Delhi AIIMS to begin Phase 2/3 clinical trials of Bharat Biotech's nasal COVID-19 vaccine soon: Sources
Zee News
Sources said that the country`s premier hospital and research center will be starting trials within a couple of weeks and an application has been put to seek the mandatory permission of the AIIMS Ethics Committee.
New Delhi: All India Institute of Medical Sciences (AIIMS) in Delhi will be starting Phase 2/3 trials of Hyderabad-based COVID-19 vaccine manufacturer Bharat Biotech`s nasal vaccine soon, according to informed sources. Amid ongoing research in many countries to develop nasal spray to help prevent COVID -19, Bharat Biotech`s intranasal vaccine received regulatory approval for second Phase trials in August. Sources said that the country`s premier hospital and research center will be starting trials within a couple of weeks and an application has been put to seek the mandatory permission of the AIIMS Ethics Committee.More Related News